pTVG-HP

BIOLOGICAL3 trials

Sponsors

University of Wisconsin, Madison

Conditions

Castration-resistant Prostate CancerMetastatic CancerProstate Cancer

Phase 2

Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer

CompletedNCT01341652

University of Wisconsin, MadisonProstate Cancer

Start: 2011-05-23End: 2020-06-30Updated: 2021-01-20

pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer

Active, not recruitingNCT03600350

University of Wisconsin, MadisonProstate Cancer

Start: 2018-09-10End: 2027-12-31Updated: 2025-05-09

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Active, not recruitingNCT04090528

University of Wisconsin, MadisonCastration-resistant Prostate Cancer, Metastatic Cancer, Prostate Cancer

Start: 2019-10-21End: 2026-10-31Updated: 2025-12-05

Related Papers

Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer

Human Vaccines & Immunotherapeutics2024-08-295 citations

Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer

Journal for ImmunoTherapy of Cancer2023-12-0133 citations

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

Journal for ImmunoTherapy of Cancer2022-03-0147 citations

Phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) and nivolumab (Nivo) in patients (pts) with nonmetastatic, PSA-recurrent prostate cancer (PCa).

Journal of Clinical Oncology2020-02-192 citations

Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) versus GM-CSF adjuvant in patients with PSA-recurrent prostate cancer.

Journal of Clinical Oncology2019-05-204 citations

Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine

Journal for ImmunoTherapy of Cancer2018-03-1359 citations

Abstract 3945: Antigen-specific immunity and regulation as predictive biomarkers for anti-tumor vaccination

Cancer Research2016-07-15

Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (PAP) versus GM-CSF adjuvant in patients with biochemically recurrent prostate cancer.

Journal of Clinical Oncology2016-05-201 citations

Abstract B147: Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with recurrent prostate cancer (NCT01341652)

Cancer Immunology Research2016-01-012 citations

Abstract CN04-03: DNA vaccines as treatment for prostate cancer - understanding mechanisms of resistance

Molecular Cancer Therapeutics2015-12-01